Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
HAE vs. BSX: Which Stock Is the Better Value Option?
12:45pm, Monday, 26'th Aug 2024
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with th
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
10:10am, Friday, 16'th Aug 2024
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Top 3 Health Care Stocks That Are Set To Fly This Quarter
07:57am, Friday, 16'th Aug 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
06:30am, Thursday, 15'th Aug 2024
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today annou
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
08:50am, Monday, 12'th Aug 2024
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
Is Haemonetics (HAE) Stock Undervalued Right Now?
10:46am, Friday, 09'th Aug 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
10:36am, Friday, 09'th Aug 2024
Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript
01:13pm, Thursday, 08'th Aug 2024
Haemonetics Corporation (NYSE:HAE ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chi
HAE or BSX: Which Is the Better Value Stock Right Now?
12:45pm, Thursday, 08'th Aug 2024
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better
Haemonetics (HAE) Misses Q1 Earnings Estimates
08:25am, Thursday, 08'th Aug 2024
Haemonetics (HAE) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.05 per share a year ago.
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
06:00am, Thursday, 08'th Aug 2024
Financial release accessible online BOSTON , Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June
Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
10:55am, Wednesday, 07'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the pos
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 07'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire
06:00am, Tuesday, 30'th Jul 2024
BOSTON , July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, tod
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
11:20am, Monday, 29'th Jul 2024
Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.
